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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM(Median: 494 mmHg (Q1-Q3: 237-828 mmHg)), which was associated with center
experience. Overall, no signiﬁcant differences in infarct size or myocardial recovery were
demonstrated between PICSO-treated and matched control patients. However, infarct size
reduction from 2-5 days to 4-months was greater for patients treated with high (>median)
PICSOquantity, compared to those treatedwith lowPICSOquantity (less than themedian)
(41.68.2% vs 21.114.1%, p¼0.02), and also compared to their matched controls
(41.68.2% vs 27.79.9%, p¼0.04).
Conclusions: PICSO is safe after pPCI for STEMI, although feasibility was limited
and depended on center experience. Administration of high PICSO quantity was
associated with enhanced infarct size reduction, suggesting a dose-effect relationship
of PICSO on myocardial recovery.
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Background: Everolimus-eluting stent (EES) is associated with a lower rate of stent
thrombosis even in the setting of ST elevation myocardial infarction (STEMI). The aim
of this study was to compare vessel responses at 3 and 6 weeks follow-up after EES or
BMS implantation using optical coherence tomography (OCT) in STEMI patient.
Methods: We recruited patients with STEMI requiring emergent PCI and who received
EES or BMS from May 2010 to February 2014. A total of 20 STEMI patients with de
novo native coronary lesions were enrolled in this study. Ten EES and 10 BMS were
implanted in STEMI patients. All patients received dual-antiplatelet therapy (clopidogrel
75 mg/day and aspirin 100 mg/day). OCT examination was performed at 3 and 6 weeks
follow-up after EESorBMS implantation.Cross-sectional area (CSA)were analyzed at 1
mm intervals. The well-apposed coverage (covered struts/ total struts  100) were
evaluated byOCT.Mean neointimal hyperplasia (NIH) thickness and%NIH ((stent area
– lumen area)/stent area  100) were also measured. The percentage of thrombi were
calculated as the (number of CSA with thrombus/total number of CSA)  100.
Results: The well-apposed coverage at 3 weeks was 87.8% with EES, 89.0% with
BMS (p¼0.78), and at 6 weeks was 96.0% with EES, 94.7% with BMS (p¼0.72). %
NIH and mean NIH thickness were signiﬁcantly lower with EES compared with BMS
at both weeks. % thrombi was signiﬁcantly lower with EES compared with BMS at 3
weeks (11.2% vs 42.6%, p< 0.01), but was similar to EES and BMS at 6 weeks (6.1%
vs 7.6%, p¼0.68). The data are shown in Table.
Conclusions: Neointimal coverage of EES was similar to BMS at 3 and 6 weeks after
implantation. However, the incidence of thrombus was signiﬁcantly lower in EES at 3
weeks, which may explain low rate of acute and subacute stent thrombosis of EES as
compared with BMS.3 weeks 6 weeks
EES BMS p EES BMS p
No. of patients (n) 5 5 5 5
Stent diameter (mm) 3.00.2 3.30.6 0.49 2.90.5 3.00.2 0.68
Stent length (mm) 40.221.2 19.05.2 <0.05 36.016.0 21.45.9 0.09
No. of stent struts (n) 366.0229.9 181.650.5 0.118 312.0159.6 284.4118.8 0.76
OCT ﬁndings
Malapposed (%) 7.66.5 12.319.8 0.63 7.35.1 0.00.0 <0.05
Well-apposed coverage
(%)
87.84.6 89.08.1 0.78 96.04.0 94.76.3 0.72
% NIH (%) 3.80.4 5.71.3 <0.05 5.01.1 15.59.4 <0.05
Mean Thickness (mm) 61.87.1 87.823.1 <0.05 66.011.6 213.9116.6 <0.05
% thrombi (%) 11.28.0 42.618.7 <0.01 6.15.1 7.65.6 0.68
No. of total CSA (n) 186 95 180 105
No. of CSA with thrombi
(n)
15 38 11 8TCT-22
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Background: Residual intrastent thrombus is readily assessed after stenting in pri-
mary percutaneous coronary intervention (PPCI), with variable level of accuracy.
Uncertain though is association of residual intrastent thrombus on prognosis and/or
left ventricular ejection fraction (LVEF). Aim of the study was to evaluate semi-
quantitatively the relation between residual intrastent thrombus as assessed by fre-
quency domain OCT (FD-OCT) after PPCI, with LVEF at discharge.
Methods: From dicember 2012 to dicember 2013, 112 consecutive patients, treated
with PPCI, were studied. Overall underwent FD-OCT after stenting. The amount of
residual intrastent thrombus was calculated as stent area minus lumen area; the % ofJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Acintrastent thrombus area (%ThA) was calculated as thrombus area/stent area. Patients
were divided on the basis of reduced (50%) or preserved (>50%) LVEF calculated
by echocardiography at discharge. Clinical follow-up was completed for all at 1,3,6,12
months by phone interview.
Results: After PPCI, mean LVEF in all patients was 53.639.6%. LVEF>50% was
observed in 61% (69/112) of the patients, while LVEF 50% 39% (43/112). After the
procedure, overall %ThA was 4.7  1.3. Patients with preserved LVEF >50% had
signiﬁcantly less %ThA than patients with LVEF 50% (4.31.8 vs 5.34.6;
p¼0.05). MACE were observed in 9/112 patients. Patients with MACE had higher
values of %ThA than patients without MACE (6.02.5 vs 4.51.3; p¼0.09).
Conclusions: In STEMI patients treated with PPCI, LVEF 50% seems to be asso-
ciated with more %ThA than LVEF>50%. MACE are associated with higher values of
%ThA. Residual intrastent thrombus can be a negative prognostic marker in STEMI.
TCT-23
Etiology, Frequency, and Clinical Outcomes of Post-procedural Myocardial
Infarction After Successful Drug-Eluting Stent Implantation: Two-Year
Follow-up From the ADAPT-DES Study
Tomotaka Dohi1, Akiko Maehara2, Bernhard Witzenbichler3, D. Christopher Metzger4,
Michael Rinaldi5, Ernest L. Mazzaferri6, Franz-Josef Neumann7, Timothy D. Henry8,
David Cox9, Ke Xu10, Sorin Brener11, Ajay J. Kirtane12, Gary S. Mintz13,
Gregg W. Stone14
1Columbia University Medical Center and Cardiovascular Research Foundation, New
York, NY, 2Cardiovascular Research Foundation and Columbia University Medical
Center, NewYork,United States, 3Charité CampusBenjaminFranklin, Berlin,Germany,
4Wellmont CVA Heart Institute, Kingsport, United States, 5Sanger Heart and Vascular
Institute, CarolinasHealthCare System,Charlotte,United States, 6Ohio StateUniversity,
Dublin, OH, 7Universitäts-Herzzentrum Freiburg - Bad Krozingen, Bad Krozingen,
Germany, 8Cedars-Sinai Medical Center, Minneapolis, United States, 9lehigh valley
hospital, Bethlehem, USA, 10Cardiovascular Research Foundation, New York, NY,
11New York Methodist Hospital, Brooklyn, United States, 12Columbia University /
Cardiovascular Research Foundation, New York, United States, 13Cardiovascular
Research Foundation, Washington, United States, 14Columbia University Medical
Center and the Cardiovascular Research Foundation, New York, United States
Background: The frequency, causes, and impact of myocardial infarction (MI) after
successful percutaneous coronary intervention (PCI) have not been well-studied.
Methods: ADAPT-DES was a prospective, multicenter, “all-comers” study of PCI with
drug-eluting stents (DES) in 8582 pts at 11 centers in the US andGermany.After excluding
125 pts with periprocedural MI, we investigated the etiology, frequency, and long-term
consequences of post-proceduralMI after successful and uncomplicatedDES implantation.
Results: Of 8457 pts without peri-procedural MI, post-procedural MI developed
during 2-year follow-up in 263 pts (3.1%). The median [IQR] time to post-procedural
MI was 318 [129, 503] days. Post-procedural MIs were attributable to: (1) non-target
lesion-related spontaneous MI (78 pts [29.7%]); (2) secondary (supply/demand
imbalance) or indeterminate MI (64 pts [24.3%]); (3) stent thrombosis (ST) related MI
(63 pts [24.0%]); and (4) in-stent restenosis (ISR) related MI (58 pts [22.1%]). Pts who
experienced a post-procedural MI had signiﬁcantly greater 2-year mortality than those
without MI (17.3% vs 3.4%, P< 0.001). The impact of post-procedural MI according
to etiology appears in the Figure. After adjustment for important clinical covariates,
the occurrence of post-procedural MI was associated with a 6.7-fold higher risk of
death at 2 years (95% CI 4.8 to 9.4, p< 0.001).Conclusions: Post-procedural MI within 2 years of successful DES implantation is
relatively infrequent but has numerous etiologies and is a strong independent predictor
of subsequent mortality.ute Myocardial Infarction B7
